Governance, regulation and public trust in xenotransplantation

Overview

Recent advances in clinical xenotransplantation, including authorised expanded-access procedures and the approval of initial kidney and liver trials, have generated urgent regulatory and governance questions. Key concerns include determination of regulatory jurisdiction, design of consent processes that reflect novel infectious and immunological risks, establishment of long-term surveillance and data-sharing systems, and management of public communication to preserve trust. Cross-jurisdictional variation in legal frameworks and institutional capacity amplifies complexity for trial initiation and post-trial oversight.

Methods and approach

Comparative legal and policy analysis of existing national regulatory models was conducted, combined with synthesis of regulatory guidance documents, expanded-access precedents, and reported clinical cases. Stakeholder mapping identified roles for health regulators, research ethics committees, professional colleges, and public health agencies. Risk governance constructs were applied to assess gaps in informed consent, biosurveillance, liability allocation, and international coordination. The approach prioritized systemic governance functions over technological or clinical efficacy considerations.

Results

Persistent regulatory ambiguities were identified regarding the lead authority for xenotransplant trials where responsibilities span biologics, devices, and clinical procedures. Informed consent frameworks inadequately address transmissible and unknown long-term risks, intergenerational considerations, and conditions for withdrawal or data use. Existing post-procedural monitoring infrastructures are insufficient for indefinite surveillance, pathogen screening, and genomic data custodianship. Fragmentation across jurisdictions impedes data harmonisation, adverse-event reporting, and reciprocal approval pathways. Public awareness and trust were found to be uneven, with potential for early high-profile failures to produce wider distrust in related biomedical research.

Implications

Implementation of clinical xenotransplantation requires establishment of clear regulatory leadership, standardized consent elements reflecting extended infectious risks, and legally durable long-term surveillance mandates with interoperable data standards. International cooperation mechanisms are necessary to enable cross-border reporting, sample sharing, and harmonised safety thresholds while addressing differential legal regimes. Proactive, evidence-based public engagement and transparent governance structures are critical to maintain institutional trust and to ensure that trial authorisation rests on robust social and ethical legitimacy as well as scientific rationale.